Molecular Partners Publishes Invitation to Annual General Meeting 2017

Zurich-Schlieren, April 13, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published the Invitation to the Annual General Meeting 2017.

The Annual General Meeting will be held on Thursday, May 11, 2017, 2.00 pm CET (doors open at 1.00 pm), at the SIX Swiss Exchange Convention Point Conference Center, Room Exchange, Selnaustrasse 30, 8021 Zurich.

Link to the Invitation to the Annual General Meeting 2017 with the corresponding agenda items.

Link zur Einladung zur Generalversammlung 2017 mit den zugehörigen Traktandenpunkten.

Financial Calendar

http://investors.molecularpartners.com/financial-calendar-and-events/

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact: